Malaysian Genomics Resource Centre Berhad Toekomstige groei

Future criteriumcontroles 0/6

Momenteel beschikken we niet over voldoende analisten om de groei en omzet voor Malaysian Genomics Resource Centre Berhad te voorspellen.

Belangrijke informatie

n/a

Groei van de winst

n/a

Groei van de winst per aandeel

Life Sciences winstgroei	27.1%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	None
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Recent updates

Is Now An Opportune Moment To Examine Malaysian Genomics Resource Centre Berhad (KLSE:MGRC)?

Mar 02

We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth

Feb 15

Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth

Nov 02

In dit gedeelte presenteren we gewoonlijk prognoses voor de omzet- en winstgroei op basis van de consensusramingen van professionele analisten om beleggers te helpen begrijpen in hoeverre het bedrijf in staat is winst te genereren. Maar omdat Malaysian Genomics Resource Centre Berhad onvoldoende gegevens uit het verleden heeft verstrekt en geen analistenprognose heeft, kan de toekomstige winst niet betrouwbaar worden berekend door gegevens uit het verleden te extrapoleren of analistenprognoses te gebruiken.

Dit is een vrij zeldzame situatie, aangezien 97% van de bedrijven die worden gedekt door SimplyWall St wel financiële gegevens uit het verleden hebben.

Winst- en omzetgroeiprognoses

KLSE:MGRC - Toekomstschattingen van analisten en financiële gegevens uit het verleden (MYR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
6/30/2024	10	-8	N/A	N/A	N/A
3/31/2024	11	-18	N/A	N/A	N/A
12/31/2023	10	-19	-17	-17	N/A
6/30/2023	8	-14	-23	-22	N/A
3/31/2023	12	1	-21	-20	N/A
12/31/2022	17	6	-20	-19	N/A
9/30/2022	23	8	-11	-9	N/A
6/30/2022	28	7	-1	0	N/A
3/31/2022	22	1	-3	2	N/A
12/31/2021	19	-1	-6	-1	N/A
9/30/2021	11	-3	-9	-5	N/A
6/30/2021	2	-4	-7	-3	N/A
3/31/2021	-3	-31	12	14	N/A
12/31/2020	-4	-33	13	16	N/A
9/30/2020	1	-7	10	13	N/A
6/30/2020	1	-6	9	12	N/A
3/31/2020	5	20	-7	-7	N/A
12/31/2019	5	21	-7	-7	N/A
9/30/2019	0	-5	-3	-2	N/A
6/30/2019	0	-5	-3	-1	N/A
3/31/2019	7	-4	-6	-4	N/A
12/31/2018	13	-5	-7	-4	N/A
9/30/2018	20	-5	-7	-5	N/A
6/30/2018	26	-5	-7	-6	N/A
3/31/2018	23	-3	N/A	1	N/A
12/31/2017	18	-1	N/A	4	N/A
9/30/2017	13	-1	N/A	4	N/A
6/30/2017	10	1	N/A	4	N/A
3/31/2017	9	0	N/A	3	N/A
12/31/2016	9	1	N/A	1	N/A
9/30/2016	10	2	N/A	3	N/A
6/30/2016	10	2	N/A	4	N/A
3/31/2016	12	2	N/A	0	N/A
12/31/2015	14	3	N/A	-1	N/A
9/30/2015	15	4	N/A	1	N/A
6/30/2015	14	4	N/A	0	N/A
3/31/2015	13	3	N/A	1	N/A
12/31/2014	9	0	N/A	2	N/A
9/30/2014	6	-2	N/A	-2	N/A
6/30/2014	4	-4	N/A	-3	N/A
3/31/2014	3	-6	N/A	-4	N/A
12/31/2013	2	-6	N/A	-2	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er zijn onvoldoende gegevens om te bepalen of de verwachte winstgroei van MGRC boven de spaarquote ( 3.6% ) ligt.

Winst versus markt: Er zijn onvoldoende gegevens om te bepalen of de winst van MGRC naar verwachting sneller zal groeien dan de markt MY

Hoge groeiwinsten: Er zijn onvoldoende gegevens om te bepalen of de winst van MGRC naar verwachting de komende 3 jaar aanzienlijk zal groeien.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van MGRC naar verwachting sneller zal groeien dan de markt MY.

Hoge groei-inkomsten: Er zijn onvoldoende gegevens om te bepalen of de omzet van MGRC naar verwachting sneller zal groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van MGRC naar verwachting over 3 jaar hoog zal zijn

Malaysian Genomics Resource Centre Berhad Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates fall by 33%

Price target decreased by 13% to RM0.95

Recent updates

New major risk - Market cap size

Malaysian Genomics Resource Centre Berhad Appoints Yap Kok Wei as Independent and Non Executive Director

New major risk - Revenue and earnings growth

Malaysian Genomics Resource Centre Berhad, Annual General Meeting, Apr 29, 2024

Malaysian Genomics Resource Centre Berhad, Annual General Meeting, Apr 29, 2024

Malaysian Genomics Resource Centre Berhad Announces Redesignation of Encik Muhammad Badri Bin Hussin to Chief Operating Officer from Director

Full year 2023 earnings: EPS and revenues miss analyst expectations

Malaysian Genomics Resource Centre Berhad Announces Update on Material Litigation

Malaysian Genomics Resource Centre Berhad Appoints Mohammad Hasni Bin Ibrahim as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Appoints Datuk Wira Muhammad Faizal Bin Zainol as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Re-Designation of Aswath A/L Ramakrishnan as A Non-Audit and Risk Management Committee Member

Malaysian Genomics Resource Centre Berhad Provides Material Litigation Update

Malaysian Genomics Resource Centre Berhad Appoints Encik Muhammad Badri Bin Hussin, Age 50, as Member of Audit Committee, Date of Change 25 Oct 2023

Malaysian Genomics Resource Centre Berhad Announces Appointment of Encik Muhammad Badri Bin Hussin as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Appointment of Encik Mohamad Ruzaini Bin Hamzah as Independent and Non Executive Director

Malaysian Genomics Resource Centre Berhad Announces Resignation of Encik Sasha Omar Firdaus Bin Aamir Nordin as Chief Executive Officer

Full year 2023 earnings released: RM0.11 loss per share (vs RM0.059 profit in FY 2022)

Malaysian Genomics Resource Centre Berhad Announces Resignation of Aswath A/L Ramakrishnan as Independent and Non Executive Member of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Appoints Miss Chih Yi May as Independent and Non Executive Director effective June 1, 2023

High number of new and inexperienced directors

Consensus revenue estimates fall by 33%

Malaysian Genomics Resource Centre Berhad Appoints Encik Syed Zulkifli Bin Syed Ismail as Independent and Non Executive Member of Nomination and Remuneration Committee

Third quarter 2023 earnings released: RM0.022 loss per share (vs RM0.016 profit in 3Q 2022)

Malaysian Genomics Resource Centre Berhad Re-designates Encik Mohd Shakir Bin Shahimi to Chairman of Audit Committee

Malaysian Genomics Resource Centre Berhad Appoints Mr. Aswath A/L Ramakrishnan as Independent and Non Executive Director

Is Now An Opportune Moment To Examine Malaysian Genomics Resource Centre Berhad (KLSE:MGRC)?

Price target decreased by 13% to RM0.95

Second quarter 2023 earnings released: RM0.01 loss per share (vs RM0.008 profit in 2Q 2022)

First quarter 2023 earnings released: EPS: RM0.007 (vs RM0.002 in 1Q 2022)

Malaysian Genomics Resource Centre Berhad Announces the Re-Designation of Encik Mohd Shakir Bin Shahimi from Member of Nomination and Remuneration Committee to Chairman of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Announces Resignation of Teoh Ai Ling as Principal Officer

Full year 2022 earnings released: EPS: RM0.059 (vs RM0.04 loss in FY 2021)

High number of new and inexperienced directors

Full year 2022 earnings released: EPS: RM0.059 (vs RM0.04 loss in FY 2021)

Malaysian Genomics Resource Centre Berhad Appoints Encik Mohd Shakir Bin Shahimi as Member of Nomination and Remuneration Committee

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad announces redesignation of Dato' Seri Dr. Chen Chaw Min from Independent Director to Independent and Non Executive Chairman

Others Malaysian Genomics Announces Board Changes

Malaysian Genomics Resource Centre Berhad Appoints Ku Chong Hong, Designation Chairman of Nomination and Remuneration Committee Directorate Independent and Non Executive, Date of Change 13 Jul 2022

Third quarter 2022 earnings released: EPS: RM0.016 (vs RM0.002 in 3Q 2021)

High number of new and inexperienced directors

Malaysian Genomics Resource Centre Berhad Announces the Launch of Its Genetic Screening Plus Personalised Health Supplements Solutions on the Airasia Super App

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Malaysian Genomics Resource Centre Berhad Announces Re-Designation of Encik Noor Azri Bin Dato' Sri Noor Azerai as Independent Executive Director

We Think Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Can Afford To Drive Business Growth

High number of new and inexperienced directors

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

Financial Controller Sek Cheah has left the company

Senior Independent Non-Executive Chairman Rafiah Salim has left the company

Companies Like Malaysian Genomics Resource Centre Berhad (KLSE:MGRC) Are In A Position To Invest In Growth

Full year 2021 earnings released: RM0.04 loss per share (vs RM0.062 loss in FY 2020)

High number of new directors

New 90-day high: RM1.22

New 90-day high: RM1.18

New 90-day high: RM1.11

New 90-day high: RM0.80

Malaysian Genomics Resource Centre Berhad Renames the Audit Committee as Audit and Risk Management Committee

First quarter 2021 earnings released: RM0.008 loss per share

New 90-day high: RM0.64

Malaysian Genomics Resource Centre Berhad Announces Appointment of ENCIK SASHA OMAR FIRDAUS BIN AAMIR NORDIN as Chief Executive Officer

New 90-day high - RM0.53

Malaysian Genomics Resource Centre Berhad Announces Resignation of Encik Robert George Hercus @ Abdul Karim Hercus as Executive Managing Director

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven